Human papillomavirus 16 E5 up-regulates the expression of vascular endothelial growth factor through the activation of epidermal growth factor receptor, MEK/ERK1,2 and PI3K/Akt

被引:107
作者
Kim, SH
Juhnn, YS
Kang, S
Park, SW
Sung, MW
Bang, YJ
Song, YS
机构
[1] Seoul Natl Univ, Inst Canc Res, Seoul 110744, South Korea
[2] Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Seoul 110744, South Korea
[3] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea
[4] Seoul Natl Univ, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, Seoul 110744, South Korea
[5] Seoul Natl Univ, Coll Med, Dept Obstet & Gynecol, Seoul 110744, South Korea
关键词
human papillomavirus; E5; oncoprotein; vascular endothelial growth factor; epidermal growth factor receptor;
D O I
10.1007/s00018-005-5561-x
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The E5 oncoprotein of human papillomavirus (HPV) 16 plays an important role in early cervical carcinogenesis. Vascular endothelial growth factor (VEGF) plays a central role in switching on the angiogenic phenotype during early cervical carcinogenesis. However, the relationship between E5 and VEGF has not previously been examined. To clarify the regulatory role of E5 in VEGF expression, we transferred the E5 gene into various cell types. E5 increased VEGF expression. The addition of epidermal growth factor receptor (EGFR) inhibitor significantly suppressed VEGF expression, demonstrating that E5 stimulates VEGF expression through the activation of EGFR. E5-mediated EGFR activation was accompanied by phosphorylation of Akt and ERK1/2, which are also involved in VEGF expression. Furthermore, the mRNA stability of VEGF was not affected by E5, but VEGF promoter activity could be modulated by inhibitors of the EGFR, MEK-ERK1/2 and PI3K/Akt pathways in E5-expressing cells. Collectively, these novel results suggest that HPV 16 E5 increases VEGF expression by activating EGFR, MEK/ERK1/2 and PI3K/Akt.
引用
收藏
页码:930 / 938
页数:9
相关论文
共 42 条
[1]   PD-098059 IS A SPECIFIC INHIBITOR OF THE ACTIVATION OF MITOGEN-ACTIVATED PROTEIN-KINASE KINASE IN-VITRO AND IN-VIVO [J].
ALESSI, DR ;
CUENDA, A ;
COHEN, P ;
DUDLEY, DT ;
SALTIEL, AR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (46) :27489-27494
[2]   STRUCTURAL AND TRANSCRIPTIONAL ANALYSIS OF HUMAN PAPILLOMAVIRUS TYPE-16 SEQUENCES IN CERVICAL-CARCINOMA CELL-LINES [J].
BAKER, CC ;
PHELPS, WC ;
LINDGREN, V ;
BRAUN, MJ ;
GONDA, MA ;
HOWLEY, PM .
JOURNAL OF VIROLOGY, 1987, 61 (04) :962-971
[3]  
Bancroft CC, 2001, CLIN CANCER RES, V7, P435
[4]   Vascular endothelial growth factor is modulated in vascular muscle cells by estradiol, tamoxifen, and hypoxia [J].
Bausero, P ;
Ben-Mahdi, MH ;
Mazucatelli, JP ;
Bloy, C ;
Perrot-Applanat, M .
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2000, 279 (05) :H2033-H2042
[5]   Insulin up-regulates vascular endothelial growth factor and stabilizes its messengers in endometrial adenocarcinoma cells [J].
Bermont, L ;
Lamielle, F ;
Lorchel, F ;
Fauconnet, S ;
Esumi, H ;
Weisz, A ;
Adessi, GL .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (01) :363-368
[6]  
Bermont L, 2000, INT J CANCER, V85, P117, DOI 10.1002/(SICI)1097-0215(20000101)85:1<117::AID-IJC21>3.0.CO
[7]  
2-X
[8]   VASCULAR-PERMEABILITY FACTOR (VASCULAR ENDOTHELIAL GROWTH-FACTOR) GENE IS EXPRESSED DIFFERENTIALLY IN NORMAL-TISSUES, MACROPHAGES, AND TUMORS [J].
BERSE, B ;
BROWN, LF ;
VANDEWATER, L ;
DVORAK, HF ;
SENGER, DR .
MOLECULAR BIOLOGY OF THE CELL, 1992, 3 (02) :211-220
[9]   Vascular endothelial growth factor in cervical carcinoma [J].
Cheng, WF ;
Chen, CA ;
Lee, CN ;
Chen, TM ;
Hsieh, FJ ;
Hsieh, CY .
OBSTETRICS AND GYNECOLOGY, 1999, 93 (05) :761-765
[10]   Vascular endothelial growth factor and prognosis of cervical carcinoma [J].
Cheng, WF ;
Chen, CA ;
Lee, CN ;
Wei, LH ;
Hsieh, FJ ;
Hsieh, CY .
OBSTETRICS AND GYNECOLOGY, 2000, 96 (05) :721-726